NCT05477784

Brief Summary

This trial examines the usefulness of two educational programs for parents with late-stage cancer who have a 5 - 17 year old child. The programs are designed to enhance the quality of the parent-child relationship and add to the parent's confidence in managing the impact of their cancer on their child. Educational programs may reduce anxiety and depression and improve the well-being and quality of life of parents with advanced cancers and their children. Recruitment occurs nationally via referral to the Fred Hutch/University of Washington Cancer Consortium team.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
174

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Jul 2022

Typical duration for not_applicable

Geographic Reach
1 country

2 active sites

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

July 19, 2022

Completed
Same day until next milestone

Study Start

First participant enrolled

July 19, 2022

Completed
9 days until next milestone

First Posted

Study publicly available on registry

July 28, 2022

Completed
2.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 21, 2025

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

August 15, 2025

Completed
Last Updated

January 21, 2026

Status Verified

June 1, 2025

Enrollment Period

2.8 years

First QC Date

July 19, 2022

Last Update Submit

January 16, 2026

Conditions

Outcome Measures

Primary Outcomes (5)

  • Treatment efficacy assessed by parents' mood (CES-D)

    Depressed mood will be measured by the 20-item Center for Epidemiological Studies- Depression Scale (CES-D) (Benazon \& Coyne, 2000; Lewis, Fletcher, Cochrane, \& Fann, 2008; Radloff, 1977). The CES-D Scale measures the recent occurrence of symptoms of depression. For each symptom, the respondent indicates the frequency with which that symptom has occurred during the past week, from "rarely or none of the time (less than 1 day)" to "most or all of the time (5-7 days)." This measure has been well- accepted in both ill and non-ill samples. Internal consistency in three samples from the general population has been reported by Radloff (Radloff, 1977) and ranged between .84 to .85. Validity has been well- established, including its link to the broader concept of "distress" in cancer-related research (Benazon \& Coyne, 2000; Coyne et al., 1987; Given et al., 2004) The internal consistency reliability is 0.85 or higher (Benazon \& Coyne, 2000; Coyne et al., 1987; Given et al., 2004).

    At 3 months post-baseline

  • Treatment efficacy assessed by parents' anxiety [Spielberger State-Trait Anxiety (STAI, state scale)]

    State anxiety will be measured by the state component of the State-Trait Anxiety Inventory. This 20-item self-report questionnaire evaluates current feelings of apprehension, tension, nervousness, and worry. The respondent circles a response that best depicts their current feelings best. Response options range from \[1 - Not at all\] to \[5 - Very much so\]. Sample items include "I feel calm", I am tense." Higher scores denote greater anxiety. Internal consistency reliability is 0.90 or above in community and population samples \[Edwards and Clarke, 2004\]

    At 3 months post-baseline

  • Parent's confidence in being able to talk with her child about the child's cancer-related concerns (CASE Help Child Subscale)

    Parenting Self-efficacy: Measured by the Help Child subscale of the parent-reported cancer Self-efficacy Scale (CASE). The Help Child subscale (9 items) measures the parent's confidence in being able to talk with her child about the child's cancer-related concerns; e.g., "I can assist my child to talk out his/her worries about my cancer." Structured response options range from "Not at all confident" (1) to "Very confident." The internal consistency reliability The internal consistency reliabilities in the EC seminal trial with parents with early stage cancer was 0.97.

    At 3 months post-baseline

  • Parents' skills in helping their child cope and manage the toll of the parents' cancer (Connecting and Coping Subscale)

    Parenting skills will be measured by the parent reported Parenting Skills Checklist: Connecting and Coping subscale developed by the study team and tested for reliability and validity in a 6-state randomized control trial (Lewis et al., 2015). The measure describes the observable interactional behaviors parents can use to assist their child disclose, discuss, and cope with the parent's cancer. The developmental-contextual model of parenting was the conceptual basis for the measure. An example item on the Connecting and Coping subscale includes, "I work with my child to help my child manage the child's stress related to my cancer."

    At 3 months post-baseline

  • Child-Behavioral Emotional Functioning: Anxious/Depressed, Internalizing, Externalizing scores on CBCL

    The child's behavioral-emotional adjustment will be measured by the Anxious/Depressed, Internalizing and Externalizing scores of the CBCL which is part of the Child Behavior Checklist. This measure will be obtained from both the ill parent and the non-ill parent/parent surrogate. Response options range from 0 to 2 from "Not True (as far as you know)" to "Somewhat or Sometimes True" to "Very True or Often True." This score is part of the Internalizing score of the CBCL that measures the child's fearful, inhibited, and over-controlled behavior. The internal consistency reliabilities for the EC clinical trial were 0.90 for the Internalizing score and 0.94 for the Externalizing score. For the current study, we will use the CBCL form for 6-18 year-olds and its computer software.

    At 3 months post-baseline

Secondary Outcomes (1)

  • Effects of parents' symptom burden on treatment outcomes: Condensed Memorial Symptom Assessment scale (CMSAS) - Physiological symptoms subscale

    At 3-months post-baseline

Study Arms (2)

Group I (enhancing connections-palliative care program)

EXPERIMENTAL

Patients receive the 5-session EC-PC program bi-weekly with a patient educator about ways to help them talk to and support their child.

Other: Educational InterventionOther: Questionnaire Administration

Group II (educational material)

ACTIVE COMPARATOR

Patients receive carefully selected educational booklet that discuss ways to talk about their cancer with their child and a scripted phone call from a trained phone counselor on study.

Other: Informational InterventionOther: Questionnaire Administration

Interventions

Receive EC-PC program

Also known as: Education for Intervention, Intervention by Education, Intervention through Education
Group I (enhancing connections-palliative care program)

Receive education booklet

Group II (educational material)

Ancillary studies

Group I (enhancing connections-palliative care program)Group II (educational material)

Eligibility Criteria

Age23 Years - 68 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Parents with any type of late-stage, non-curable cancer (determined by TNM stage IV cancer for solid tumors or 2 or more cycles of treatment failure with disease relapse in non-solid tumors)
  • All therapies are allowable
  • years (yr.) to 68 yr. Age restriction exists for the patient based on parent having a child ages 5-17
  • Patient must have a child (5yr. -17 yr.) living in the home at least 50% of the time and residential with non-ill parent or parent surrogate
  • Read and write English as one of their languages of choice
  • Have access to a telephone
  • Ability to understand and the willingness to sign a written informed consent document. Read and write English as one of their languages of choice

You may not qualify if:

  • Patient is in hospice at time of enrollment
  • Non-ill co-parent does not consent to join study

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

Georgetown University

Washington D.C., District of Columbia, 20007, United States

Location

Fred Hutch/University of Washington Cancer Consortium

Seattle, Washington, 98115, United States

Location

MeSH Terms

Conditions

Neoplasms

Interventions

Early Intervention, EducationalEducational StatusMethods

Intervention Hierarchy (Ancestors)

Child Health ServicesCommunity Health ServicesHealth ServicesHealth Care Facilities Workforce and ServicesPreventive Health ServicesSocioeconomic FactorsPopulation CharacteristicsInvestigative Techniques

Study Officials

  • Frances M Lewis, RN, MN, PhD

    University of Washington

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR
Masking Details
Only biostatistician will be unmasked.
Purpose
SUPPORTIVE CARE
Intervention Model
PARALLEL
Model Details: 2-group randomized control trial: experimental and alternative treatment control group
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

July 19, 2022

First Posted

July 28, 2022

Study Start

July 19, 2022

Primary Completion

May 21, 2025

Study Completion

August 15, 2025

Last Updated

January 21, 2026

Record last verified: 2025-06

Data Sharing

IPD Sharing
Will share

Secondary analysis of data will be permitted after a specific plan is submitted to the Principal Investigator and Co-Investigators approve. Plan should make explicit the analysis sample, rationale for study, aims of secondary analysis, proposed data analysis to be used, timeline for completion of analysis, and agreement to cite the parent study with appropriate acknowledgment.

Shared Documents
STUDY PROTOCOL, SAP, ICF, CSR
Time Frame
Data will become available after filing FINAL Report to NINR, NIH and after the efficacy results and analysis of study aims are published.
Access Criteria
Scientists prepared with a PhD or equivalent degree will be granted access for secondary analysis, after their specific proposed plan is submitted and reviewed by PI and Co-Invesigators.

Locations